Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

Source :: GlobeNewswire. July 29, 2024
Publication Year :: 2024
Abstract: PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the [...]

Subjects :: Lichen planus -- Drug therapy
Drug approval
Clinical trials
Banking, finance and accounting industries
Business

Tools